文献速递肝病消化道肿瘤与早癌

肿瘤源性PGLYRP2预测肝细胞癌生存与抗肿瘤免疫应答

Tumor-Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2020-01-24

肝细胞癌(HCC)与免疫抑制相关。研究探讨PGLYRP2是否通过调节宿主抗肿瘤免疫影响HCC进展。结果显示PGLYRP2在HCC中下调且与不良预后相关(P < 0.001),过表达可增强免疫健全小鼠的抗肿瘤免疫应答,机制涉及DNA甲基转移酶3A介导的启动子高甲基化及CCL5产生增加。

要点

  • PGLYRP2在HCC中下调,与不良预后相关(P < 0.001)。
  • PGLYRP2过表达增强免疫健全小鼠抗肿瘤免疫应答。
  • PGLYRP2通过结合CCL5启动子促进CCL5产生。

核心结论

  • 肿瘤源性PGLYRP2可作为HCC充分免疫应答和改善患者结局的候选生物标志物。

研究设计与样本

  • 研究探讨PGLYRP2是否通过调节宿主抗肿瘤免疫影响HCC进展,包括HCC细胞过表达实验和免疫健全小鼠模型。

主要发现

  • PGLYRP2在HCC中下调,与患者不良预后相关(P < 0.001)。
  • HCC细胞中PGLYRP2过表达显著增强免疫健全小鼠的抗肿瘤免疫应答,并提高外周血单核细胞对HCC的免疫应答率。
  • DNA甲基转移酶3A介导的启动子高甲基化导致HCC中PGLYRP2下调。
  • PGLYRP2通过结合CCL5启动子促进HCC中CCL5产生,从而增强抗肿瘤免疫。

关键数值与推荐

  • PGLYRP2在HCC中下调与不良预后相关,原文报告P < 0.001。

临床怎么用

  • PGLYRP2可能作为HCC免疫应答和预后评估的候选生物标志物。
  • PGLYRP2及其下游CCL5通路可能为HCC免疫治疗设计提供靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is linked to immunosuppression. Relieving immunosuppression has been an attractive strategy to improve the efficacy of cancer immunotherapy. Peptidoglycan recognition protein 2 (PGLYRP2) is a pattern recognition receptor which is specifically expressed in liver and implicated in the regulation of innate immunity and immunosurveillance. However, the role of hepatic PGLYRP2 in modulating immune responses against HCC remains to be investigated. APPROACH AND RESULTS: In this study, we investigated whether PGLYRP2 is able to influence HCC progression through regulating host antitumor immune responses. We demonstrated that PGLYRP2 was down-regulated in HCC, which was linked with poor prognosis in patients (P < 0.001). PGLYRP2 overexpression in HCC cells significantly enhanced antitumor immune responses in immune-competent mice and elevated immune response rates of peripheral blood mononuclear cells against HCC. Mechanistically, DNA methyltransferase 3A-mediated promoter hypermethylation was responsible for the down-regulation of PGLYRP2 in HCC. PGLYRP2 promoted production of chemokine (C-C motif) ligand 5 (CCL5) in HCC through binding to the CCL5 promoter, which contributed to the enhanced antitumor immunity. CONCLUSIONS: We provide evidence that tumor-derived PGLYRP2 acts as a candidate biomarker for adequate immune response against HCC and improved patient outcomes, indicating the importance of hepatic PGLYRP2 in cancer immunosurveillance and in designing immunotherapeutic approaches.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Yang Z, Feng J, Xiao L, et al. Tumor-Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology. 2020. PMID: 31479523. doi:10.1002/hep.30924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。